MX2020003706A - Aminoimidazopiridazinas como inhibidores de cinasa. - Google Patents
Aminoimidazopiridazinas como inhibidores de cinasa.Info
- Publication number
- MX2020003706A MX2020003706A MX2020003706A MX2020003706A MX2020003706A MX 2020003706 A MX2020003706 A MX 2020003706A MX 2020003706 A MX2020003706 A MX 2020003706A MX 2020003706 A MX2020003706 A MX 2020003706A MX 2020003706 A MX2020003706 A MX 2020003706A
- Authority
- MX
- Mexico
- Prior art keywords
- aminoimidazopyridazines
- kinase inhibitors
- kinase
- inhibitors
- empty
- Prior art date
Links
- VUKTWKAEOMJKEE-UHFFFAOYSA-N 5h-imidazo[4,5-c]pyridazin-3-amine Chemical class N1N=C(N)C=C2N=CN=C21 VUKTWKAEOMJKEE-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762578607P | 2017-10-30 | 2017-10-30 | |
| US201862626853P | 2018-02-06 | 2018-02-06 | |
| PCT/US2018/057968 WO2019089442A1 (en) | 2017-10-30 | 2018-10-29 | Aminoimidazopyridines as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003706A true MX2020003706A (es) | 2020-07-22 |
Family
ID=64332173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003706A MX2020003706A (es) | 2017-10-30 | 2018-10-29 | Aminoimidazopiridazinas como inhibidores de cinasa. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11440913B2 (enExample) |
| EP (1) | EP3704118B1 (enExample) |
| JP (1) | JP7228586B2 (enExample) |
| KR (1) | KR102662197B1 (enExample) |
| CN (1) | CN111566103B (enExample) |
| AU (1) | AU2018361249B2 (enExample) |
| BR (1) | BR112020007557A2 (enExample) |
| CA (1) | CA3080402A1 (enExample) |
| CY (1) | CY1124984T1 (enExample) |
| DK (1) | DK3704118T3 (enExample) |
| ES (1) | ES2905948T3 (enExample) |
| HR (1) | HRP20220297T1 (enExample) |
| HU (1) | HUE058292T2 (enExample) |
| IL (1) | IL274207B2 (enExample) |
| LT (1) | LT3704118T (enExample) |
| MX (1) | MX2020003706A (enExample) |
| PL (1) | PL3704118T3 (enExample) |
| PT (1) | PT3704118T (enExample) |
| RS (1) | RS62974B1 (enExample) |
| SG (1) | SG11202003824PA (enExample) |
| SI (1) | SI3704118T1 (enExample) |
| SM (1) | SMT202200087T1 (enExample) |
| WO (1) | WO2019089442A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2902676T3 (es) | 2017-02-13 | 2022-03-29 | Bristol Myers Squibb Co | Aminotriazolopiridinas como inhibidores de cinasa |
| CA3088548A1 (en) | 2018-01-26 | 2019-08-01 | Bristol-Myers Squibb Company | Aminopyrrolotriazines as kinase inhibitors |
| BR112021004310A2 (pt) | 2018-09-13 | 2021-05-25 | Bristol-Myers Squibb Company | indazolcarboxamidas como inibidores de cinase |
| BR112021004385A2 (pt) | 2018-09-13 | 2021-07-20 | Bristol-Myers Squibb Company | 1h-indazol carboxamidas como inibidores de proteína quinase de interação com o receptor 1 (ripk1) |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| US12275721B2 (en) | 2019-10-03 | 2025-04-15 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| WO2021168521A1 (en) * | 2020-02-27 | 2021-09-02 | Anaxis Pharma Pty Ltd | Inhibitors of necroptosis |
| CN114262322A (zh) * | 2020-09-16 | 2022-04-01 | 中国科学院上海有机化学研究所 | 一类细胞程序性坏死抑制剂及其制备方法和用途 |
| WO2022081522A1 (en) | 2020-10-13 | 2022-04-21 | The Johns Hopkins University | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF |
| AR123793A1 (es) * | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
| CN120530112A (zh) * | 2022-12-30 | 2025-08-22 | 广州市联瑞制药有限公司 | 双环类化合物及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| US7820665B2 (en) * | 2007-12-19 | 2010-10-26 | Amgen Inc. | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment |
| CA2750517A1 (en) * | 2009-02-04 | 2010-08-12 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| BR112014030147B1 (pt) | 2012-06-22 | 2019-10-15 | Sumitomo Chemical Company, Limited | Compostos heterocíclicos fundidos, composição e método para controlar pestes |
| EP2897949B1 (en) | 2012-09-18 | 2018-01-10 | Bristol-Myers Squibb Company | Iap antagonists |
| ES2749467T3 (es) | 2012-11-20 | 2020-03-20 | Biogen Ma Inc | Agentes moduladores de S1p y/o ATX |
| EP2970266B1 (en) | 2013-03-15 | 2018-01-31 | Epizyme, Inc. | 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof |
| CN105246891A (zh) | 2013-06-10 | 2016-01-13 | 拜耳制药股份公司 | 用于治疗癌症的新化合物 |
| WO2016027253A1 (en) | 2014-08-21 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
| WO2017192930A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| WO2018017435A1 (en) | 2016-07-22 | 2018-01-25 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof |
| ES2902676T3 (es) | 2017-02-13 | 2022-03-29 | Bristol Myers Squibb Co | Aminotriazolopiridinas como inhibidores de cinasa |
| CA3088548A1 (en) | 2018-01-26 | 2019-08-01 | Bristol-Myers Squibb Company | Aminopyrrolotriazines as kinase inhibitors |
| BR112021004385A2 (pt) | 2018-09-13 | 2021-07-20 | Bristol-Myers Squibb Company | 1h-indazol carboxamidas como inibidores de proteína quinase de interação com o receptor 1 (ripk1) |
| BR112021004310A2 (pt) | 2018-09-13 | 2021-05-25 | Bristol-Myers Squibb Company | indazolcarboxamidas como inibidores de cinase |
| EP3877371A4 (en) * | 2018-11-07 | 2022-07-27 | Dana-Farber Cancer Institute, Inc. | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES USED AS JANUS KINASE 2 INHIBITORS AND ASSOCIATED USES |
-
2018
- 2018-10-29 MX MX2020003706A patent/MX2020003706A/es unknown
- 2018-10-29 EP EP18804177.6A patent/EP3704118B1/en active Active
- 2018-10-29 SM SM20220087T patent/SMT202200087T1/it unknown
- 2018-10-29 SG SG11202003824PA patent/SG11202003824PA/en unknown
- 2018-10-29 PL PL18804177T patent/PL3704118T3/pl unknown
- 2018-10-29 US US16/758,892 patent/US11440913B2/en active Active
- 2018-10-29 JP JP2020524156A patent/JP7228586B2/ja active Active
- 2018-10-29 ES ES18804177T patent/ES2905948T3/es active Active
- 2018-10-29 LT LTEPPCT/US2018/057968T patent/LT3704118T/lt unknown
- 2018-10-29 KR KR1020207015195A patent/KR102662197B1/ko active Active
- 2018-10-29 DK DK18804177.6T patent/DK3704118T3/da active
- 2018-10-29 AU AU2018361249A patent/AU2018361249B2/en not_active Ceased
- 2018-10-29 RS RS20220215A patent/RS62974B1/sr unknown
- 2018-10-29 HR HRP20220297TT patent/HRP20220297T1/hr unknown
- 2018-10-29 SI SI201830556T patent/SI3704118T1/sl unknown
- 2018-10-29 PT PT188041776T patent/PT3704118T/pt unknown
- 2018-10-29 CA CA3080402A patent/CA3080402A1/en active Pending
- 2018-10-29 WO PCT/US2018/057968 patent/WO2019089442A1/en not_active Ceased
- 2018-10-29 CN CN201880084047.7A patent/CN111566103B/zh active Active
- 2018-10-29 BR BR112020007557-4A patent/BR112020007557A2/pt not_active IP Right Cessation
- 2018-10-29 HU HUE18804177A patent/HUE058292T2/hu unknown
-
2020
- 2020-04-24 IL IL274207A patent/IL274207B2/en unknown
-
2022
- 2022-03-08 CY CY20221100117T patent/CY1124984T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL274207B2 (en) | 2023-04-01 |
| JP2021501179A (ja) | 2021-01-14 |
| SMT202200087T1 (it) | 2022-03-21 |
| BR112020007557A2 (pt) | 2020-09-24 |
| PL3704118T3 (pl) | 2022-04-04 |
| HRP20220297T1 (hr) | 2022-05-13 |
| US20200277296A1 (en) | 2020-09-03 |
| AU2018361249A1 (en) | 2020-06-11 |
| RS62974B1 (sr) | 2022-03-31 |
| KR102662197B1 (ko) | 2024-04-29 |
| CN111566103B (zh) | 2023-06-23 |
| EP3704118A1 (en) | 2020-09-09 |
| SI3704118T1 (sl) | 2022-04-29 |
| LT3704118T (lt) | 2022-02-25 |
| CN111566103A (zh) | 2020-08-21 |
| AU2018361249B2 (en) | 2022-08-25 |
| WO2019089442A8 (en) | 2019-06-27 |
| JP7228586B2 (ja) | 2023-02-24 |
| HUE058292T2 (hu) | 2022-07-28 |
| KR20200078591A (ko) | 2020-07-01 |
| EP3704118B1 (en) | 2022-01-12 |
| CY1124984T1 (el) | 2023-01-05 |
| SG11202003824PA (en) | 2020-05-28 |
| IL274207B (en) | 2022-12-01 |
| IL274207A (en) | 2020-06-30 |
| DK3704118T3 (da) | 2022-03-14 |
| ES2905948T3 (es) | 2022-04-12 |
| WO2019089442A1 (en) | 2019-05-09 |
| CA3080402A1 (en) | 2019-05-09 |
| PT3704118T (pt) | 2022-02-14 |
| US11440913B2 (en) | 2022-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003706A (es) | Aminoimidazopiridazinas como inhibidores de cinasa. | |
| IL268614B (en) | Aminotriazolopyridines as kinase inhibitors | |
| MX2020004084A (es) | Agentes farmaceuticos como inhibidores del rsv para utilizar en combinacion. | |
| MX2020003430A (es) | Derivados de 1-bencil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de proteasa de virus de inmunodeficiencia humana. | |
| ZA201905811B (en) | Novel inhibitors | |
| MX2020004287A (es) | Procesamiento de biomasa. | |
| MX2020003760A (es) | Formulaciones de niraparib. | |
| GEP20217234B (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| SG11202100525SA (en) | Pyrrolopyrimidine itk inhibitors | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
| MX2020004255A (es) | Compuesto de pirimidina como inhibidor de las janocinasas. | |
| MX2017000363A (es) | Inhibicion de la via de notch. | |
| MX2020004424A (es) | Formulacion aerosolizable. | |
| MX2020004071A (es) | Derivados de aztreonam y usos de los mismos. | |
| MX2020004455A (es) | Derivados de pirrolopirazina como inhibidores de integrina alfa v. | |
| MX2020003439A (es) | Compuestos biciclicos para usarse como inhibidores de cinasa de la proteina 1 de interaccion con receptores (rip1). | |
| MX2020003440A (es) | Red de seguridad. | |
| MX2020002908A (es) | Composicion acuosa de polimeros. | |
| MX2020003611A (es) | Metodos de refuerzo del pozo. | |
| MX2020003578A (es) | Sal de edaravone. | |
| MX2020003487A (es) | Compuestos inhibidores de pirimidina tbk/ikkepsilon y usos de los mismos. | |
| MX2020003703A (es) | Composiciones de sabor. | |
| MX2020004048A (es) | Formas cristalinas de lenalidomida. | |
| GB201807845D0 (en) | Kinase Inhibitors |